Entries by

Poster presented at SOT 2021: Applicability domain of the GARD™skin Medical Device test for in vitro skin sensitization testing of medical devices

15 April, 2021 in , , /by

Joshua Schmidt, Ron Brown and Rose-Marie Jenvert SenzaGen Inc., Raleigh, NC, USA, Risk Science Consortium LLC, Arnold, MD, USA, SenzaGen AB, Lund, Sweden. Download a copy Conclusion The chemical space of compounds tested in GARD closely approximates the chemical space of compounds known to be released from medical device materials. GARDskin is able to predict […]

Poster presented at SOT 2021: Quantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response

15 April, 2021 in , , /by

Henrik Johansson, Robin Gradin, Andy Forreryd, Joshua Schmidt SenzaGen AB, Lund, Sweden. SenzaGen Inc., Raleigh, NC. Download a copy   Conclusion As an adaptation from the GARDskin assay, GARDskin Dose-Response is suitable for quantitative skin sensitizing potency assessment of chemicals. The experimental readout, referred to as cDV0, corresponds to the lowest dose required to elicit […]

SOT 2021 Recap: Spotlight on Dose-Response and the MDCPSS Best Overall Abstract Award Winner 🏅

26 March, 2021 in /by

SenzaGen had a busy program at SOT 2021. To highlight our expanding capabilities in in vitro skin toxicology, we took part in several activities and presented our novel assays for quantitative skin sensitizing potency assessment and medical device testing.   Exhibitor Hosted Session: Dose-response for predicting skin sensitization potency Listen to SenzaGen’s Chief Scientist Dr Henrik Johansson presenting […]

Poster presented at ACT 2020: Applicability of GARD™skin for Accurate Assessment of Challenging Substances in the Context of Skin Sensitization Testing

20 November, 2020 in , , , /by

J. Schmidt, A. Forreryd, H. Johansson, J. Li, A. Johansson SenzaGen, Inc., Raleigh, NC, USA, SenzaGen AB, Lund, Sweden   Link to the poster   Conclusion GARDskin demonstrated an overall high applicability for the evaluated challenging substances with 80% predictive accuracy compared to existing human data. GARDskin demonstrated excellent applicability for pre/pro-haptens and low water […]

Poster presented at ACT 2020: Dose-Response Analysis in GARD™ for Assessment of Skin Sensitizer Potency

20 November, 2020 in , , /by

J. Schmidt, A. Forreryd, R. Gradin2, H. Johansson. SenzaGen Inc., Raleigh, NC., SenzaGen AB, Lund, Sweden.   Link to the poster   Conclusion As an adaptation from the GARDskin assay, GARDskin Dose-Response is suitable for quantitative skin sensitizing potency assessment of chemicals. The experimental readout, referred to as cDV0, corresponds to the lowest dose required […]